This is a combined cohort study with retrospectively and prospectively enrolled coronary artery disease (CAD) patients. All the patients will undergo clinical follow-up for up to 5 years, and repeat coronary CTA will be conducted after 2 years. Comprehensive morphological and functional plaque analysis will be performed. The impact of these morphological and functional parameters, alongside cardiometabolic factors and pharmacological treatments on plaque progression and the occurrence of major adverse cardiovascular events (MACEs) will be analyzed. In addition, intracoronary imaging techniques will be used to improve the accuracy of plaque analysis by coronary CTA.
This is a combined cohort study with retrospectively and prospectively enrolled patients. Subjects with CAD detected by coronary CTA are consecutively enrolled. All the patients will undergo clinical follow-up for up to 5 years. Repeat coronary CTA will be conducted after 2 years. For patients referred to invasive coronary angiography, intracoronary imaging techniques, such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near infrared spectroscopy (NIRS) will be performed. For all the prospectively enrolled patients, plasma and serum blood samples will be collected. The purpose of this study is to investigate the natural history of coronary atherosclerotic plaques in this population. Comprehensive morphological plaque analysis will be performed to evaluate total atheroma volume (TAV), percent atheroma volume (PAV), plaque composition, high risk plaque features, and characteristics of perivascular adipose tissue (PVAT). Functional analysis will also be conducted to calculate hemodynamic parameters such as wall shear stress (WSS), oscillatory shear index (OSI), relative residence time (RTT), transverse WSS (transWSS), axis plaque stress (APS), fractional flow reserve (FFR), and δFFR across lesions. The associations of these morphological and functional parameters with plaque progression and the onset of major adverse cardiovascular events (MACEs) will be analyzed. In addition, the impact of pharmacological treatments and the levels of cardiometabolic factors on coronary plaque progression will also be investigated. In the subpopulation who also receive intracoronary imaging examinations, intracoronary imaging modalities will be used to refine the inner and outer vessel contours, improve the accuracy of plaque composition characterization, and aid in the discovery of novel high-risk plaque features by coronary CTA.
Study Type
OBSERVATIONAL
Enrollment
50,000
CAAC East China Aviation Personnel Medical Appraisal Center, Civil Aviation Shanghai Hospital
Shanghai, China
RECRUITINGRuijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
RECRUITINGChanges in total atheroma volume (TAV)
changes in TAV in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Major cardiovascular events (MACEs)
A composite endpoint of cardiovascular death, non-fatal myocardial infarction, and unplanned revascularization during follow-up
Time frame: 5 years
Cardiovascular death
The occurrence of cardiovascular death during follow-up
Time frame: 5 years
Myocardial infarction
The occurrence of myocardial infarction during follow-up
Time frame: 5 years
Unplanned revascularization
The occurrence of unplanned revascularization during follow-up
Time frame: 5 years
Changes in calcified plaque volume
Changes in calcified plaque volume in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in non-calcified plaque volume
Changes in non-calcified plaque volume in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in fibrous plaque volume
Changes in fibrous plaque volume in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in fibrousfatty plaque volume
Changes in fibrousfatty plaque volume in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in necrotic core volume
Changes in plaque necrotic core volume in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in high-risk plaque (HRP) features
Changes in the number of HRP features in whole heart and in target lesions measured by coronary CTA at baseline and during follow-up.
Time frame: 24 months
Changes in perivascular adipose tissue (PVAT) volume
Changes in the volume of PVAT measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in perivascular adipose tissue (PVAT) density
Changes in the density of PVAT measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
Changes in perivascular adipose tissue (PVAT) distribution
Changes in the distribution of PVAT measured by coronary CTA and quantification analysis at baseline and during follow-up
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.